首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到18条相似文献,搜索用时 171 毫秒
1.
目的探讨BCLCB期肝细胞癌(hepatocellular carcinoma,HCC)患者手术切除预后的影响因素。方法收集2003年3月至2007年9月169例BCLCB期HCC手术切除患者的临床病理资料,采用Kaplan-Meier法计算术后累积生存率,以Log-rank显著性检验初步筛选出可能影响HCC预后的相关因素,应用Cox回归分析进一步明确影响预后的独立因素。结果 BCLCB期HCC患者术后1、3、5年累积生存率分别为76.3%、46.0%、38.8%。单因素分析表明术前谷丙转氨酶(ALT)、肿瘤包膜、肿瘤数目、肝硬化和术后辅助治疗影响HCC术后累计生存率(P〈0.05)。多因素分析表明肿瘤包膜、肿瘤数目、肝硬化和术后辅助治疗是影响HCC术后生存率的独立因素(P〈0.05)。结论手术切除是BCLCB期HCC患者有效的治疗手段,肿瘤包膜、肿瘤数目、肝硬化和术后辅助治疗是其预后的独立影响因素。  相似文献   

2.
Hong J  Yuan YF  Li BK  Huang L  Li JQ  Zhang YQ  Li GH 《癌症》2007,26(6):620-623
背景与目的:肝细胞肝癌(下称肝癌)合并重度肝硬化,由于肝储备功能差,手术风险明显增高.本研究探讨肝癌合并重度肝硬化的手术安全性、疗效和预后影响因素.方法:回顾性分析我院1998年至2003年经手术切除的67例肝癌合并重度肝硬化的患者资料,根据随访结果计算生存率并作单因素和多因素分析.结果:3例围手术期死亡.术后1、3、5年累积生存率分别为62.6%、46.7%、19.9%.单因素分析结果表明预后影响因素为术前Child-Pugh分级、吲哚靛青绿15 min储备率(ICGR15)、血小板计数、肿瘤大小、肿瘤数目和是否根治性切除;多因素分析得出影响疗效的独立预后因素为术前Child-Pugh分级和是否根治性切除.结论:正确的术前肝储备功能评估,可增加手术切除的安全性,使部分合并重度肝硬化的肝癌患者获得手术根治的机会.术后辅助治疗有助提高患者生存率.  相似文献   

3.
肝细胞肝癌术后预后因素分析   总被引:2,自引:0,他引:2  
目的 探讨肝细胞肝癌(HCC)外科治疗后的预后影响因素.方法 回顾性分析832例外科治疗HCC患者的临床资料,采用Kaplan-Meier法进行生存分析,应用Cox比例风险模型进行多因素回归分析.结果 832例患者术后1、3、5年生存率分别为92.0%、70.2%和53.6%,术后1、3、5年无复发生存率分别为90.2%、61.5%和40.5%.单因素分析显示,无临床症状、肿瘤≤5 cm、肿瘤单发、分化程度好、无病理脉管瘤栓、血清甲胎蛋白(AFP)阴性、血清碱性磷酸酶(ALP)阴性、Child-Pugh A级、无腹水、无或轻度肝硬化、解剖性分离法切除、无围手术期输血、无腹腔淋巴结转移、无大血管侵犯以及无肿瘤破裂或肝外侵犯的HCC患者生存情况较好.Cox多因素分析显示,有无临床症状、肿瘤大小、肿瘤数目、有元病理脉管瘤栓、血清AFP、肝硬化程度、肝脏外科切除技术、有无腹腔淋巴结转移、有无大血管侵犯、有无肿瘤破裂或肝外侵犯是HCC患者术后长期生存的独立影响因素,其中有无腹腔淋巴结转移、有无大血管侵犯和有无肿瘤破裂或肝外侵犯贡献较大,RR分别为4.607、4.103和3.955.结论 HCC切除术后患者预后受多种因素影响,术前早诊早治、术中手术微创操作、术后预防肝硬化进展是改善患者术后生存的重要途径.  相似文献   

4.
原发性肝癌手术切除患者预后危险因素分析   总被引:2,自引:0,他引:2  
目的:分析影响原发性肝癌患者手术切除后总体生存率和无瘤生存率的危险因素.方法:回顾性分析186例手术切除的肝癌患者临床和病理资料,Kaplan-Meier法和log rank检验进行单因素分析,应用Cox比例风险模型进行多因素分析.结果:影响患者总体预后的独立危险因素包括AFP水平、有无包膜、TNM分期、肿瘤分布、血管侵犯和围手术期输血;影响患者无瘤生存的独立危险因素包括性别、AFP水平、有无包膜、TNM分期、肿瘤数目、肿瘤分布和围手术期输血.结论:肝癌手术切除患者预后与肿瘤进展程度以及围手术期大量输血有关.术前积极改善患者凝血功能,术中有效控制出血,减少输血对于改善患者预后可能有积极的作用.  相似文献   

5.
原发性肝癌手术切除患者预后危险因素分析   总被引:1,自引:0,他引:1  
目的:分析影响原发性肝癌患者手术切除后总体生存率和元瘤生存率的危险因素。方法:回顾性分析186例手术切除的肝癌患者临床和病理资料,Kaplan-Meier法和logrank检验进行单因素分析,应用Cox比例风险模型进行多因素分析。结果:影响思者总体预后的独立危险因素包括AFP水平、有无包膜、TNM分期、肿瘤分布、血管侵犯和围手术期输血;影响患者无瘤生存的独立危险因素包括性别、AFP水平、有无包膜、TNM分期、肿痛数目、肿瘤分布和围手术期输血。结论:肝癌手术切除患者预后与肿瘤进展程度以及围手术期大量输血有关。术前积极改善患者凝血功能,术中有效控制出血,减少输血对于改善患者预后可能有积极的作用.  相似文献   

6.
目的 探讨肝门部胆管癌(HCC)外科治疗的临床效果及预后影响因素。方法 回顾性分析行外科手术治疗的114例HCC患者临床资料,分析HCC外科治疗的临床效果及预后影响因素。结果 114例HCC患者中行根治性切除61例(53.51%),其中姑息性切除53例(46.49%),根治性切除术后出现肝功能衰竭3例,胆瘘5例,胆道感染4例,切口感染11例,姑息性切除术后出现胆道感染5例,胆漏4例;随访术后3年总体生存率为24.56%(28/114),根治性切除术后3年生存率为36.07%(22/61),高于姑息性切除术的11.32%(6/53),差异有统计学意义(P<0.05);单因素分析显示:手术方式、肿瘤分化程度、TNM分期、淋巴结转移、门静脉侵犯、合并高胆红素血症与HCC外科治疗预后有关,差异有统计学意义(P<0.05);年龄、性别、肿瘤大小、手术时间、辅助化疗、术中出血量与HCC外科治疗预后无关,差异无统计学意义(P>0.05);多因素分析显示:姑息性切除、肿瘤低分化、TNM分期T3-T4期、淋巴结转移、门静脉侵犯、合并高胆红素血症是影响HCC外科治疗预后的高危因素(P&l...  相似文献   

7.
[目的]探讨原发性透明细胞型肝癌(PCCCL)经手术切除治疗后影响预后的因素。[方法]回顾性分析广西医科大学附属肿瘤医院1996年1月至2006年12月间收治的52例PCCCL手术切除患者的临床资料,并进行单因素和多因素分析。[结果]全组患者术后l、3、5年总生存率分别为80.8%、46.2%、38.5%。多因素分析提示患者预后与甲胎蛋白水平、是否发生血管浸润、肝硬化背景和有无包膜相关。[结论]肿瘤包膜形成、大血管侵犯、甲胎蛋白水平、肝硬化背景是影响PCCCL患者预后的危险因素。  相似文献   

8.
目的:探讨肝门部胆管癌(HCC)的外科治疗特点及预后因素,以期进一步提高HCC外科疗效。方法:回顾性分析67例病理诊断为HCC患者的临床资料。结果:不同手术方法术后累计生存率差异显著(P〈0.001)。根治切除组1、3年生存率显著高于姑息切除组和单纯引流组,手术切除组较非手术切除组生存时间显著提高(P〈0.001)。术前T分期和Bithmuth分型能指导手术切除率及术式选择。不同的T分期的手术切除率及切缘阴性率差异显著(P〈0.001)。分别对16个可能影响预后的因素进行单因素预后分析表明肿瘤大小、门静脉侵犯、局部浸润及转移、手术方法、UICC分期、改良T分期、淋巴结转移对预后有影响,统计学上有显著性差异(P〈0.05)。COX模型多因素预后分析表明手术方法、UICC分期是两个独立预后因素。结论:根治性切除是最重要预后因素,扩大手术范围能获得较好切缘无癌率,术前的T分期和Bismuth分型综合评估将有助于进一步在安全的范围内提高手术切除率及根治性切除率。  相似文献   

9.
影响肝细胞癌术后长期生存的相关因素   总被引:2,自引:0,他引:2  
通过对复旦大学肝癌研究所20世纪90年代手术治疗的2333例肝细胞癌病例的分析,旨在寻找与长期生存的相关因素.其中根治性切除1465(62.8%)例,姑息性切除868例(37.2%).随访至2003年底,术后存活5年以上者527例,其中根治性切除组454例,姑息性切除组73例.根治性切除后长期生存的相关因素为肿瘤的发现途径,肿瘤大小、包膜,肿瘤细胞的分化程度,肝硬化程度,血清γ-GT水平.姑息性切除后长期生存的相关因素为肿瘤大小、肿瘤包膜、γ-GT、肝硬化程度、术后TACE和二步切除是长期生存独立的影响因素.术后复发的病人经过综合治疗后也能达到比较理想的长期生存率.  相似文献   

10.
目的 对肝细胞性肝癌患者进行手术治疗,并分析影响其术后生存率的因素.方法 选取肝细胞性肝癌患者100例,根据肿瘤大小、位置选择行肝叶、肝段、半肝和局部切除术,术后进行电话随访,分析术后生存率的影响因素.结果 肿瘤大小、术前AFP、术后AFP、血管侵犯、辅助治疗、有无肝硬化,与患者术后生存率有相关性(P<0.05),与性别、年龄、乙肝抗原、手术方式无关(P>0.05);术前术后AFP变化、血管侵犯和肝硬化是影响肝细胞性肝癌患者术后生存率的独立因素(P<0.05).结论 肿瘤大小、血管侵犯、术前AFP、术后AFP、辅助治疗、肝硬化均与肝细胞性肝癌患者手术治疗后的生存率有关;术前术后AFP、血管侵犯、肝硬化是影响肝细胞性肝癌患者术后生存率的独立因素.  相似文献   

11.
目的 探讨肝细胞癌(hepatocellular carcinoma,HCC)根治性切除术后总生存期(overall survival,OS)的影响因素.方法 回顾性收集于山东第一医科大学第二附属医院及山东大学第二医院行根治性切除术的1744例HCC患者的临床资料,采用Cox回归分析影响OS的因素,利用R语言survm...  相似文献   

12.
Objectives: To investigate the prognosis significance of preoperative serum alpha-fetoprotein (AFP) andthe correlation with clinicopathological factors of hepatocellular carcinoma (HCC) patients who underwenthepatectomy. Materials and Methods: Clinicopathological data of retrospective analysis were collected for251 HCC patients undergoing hepatectomy in this study. According to preoperative AFP level, patients werecategorized into AFP-negative (0-20ng/mL) and AFP-positive (>20 ng/mL) groups for Kaplan-Meier analysisand Cox proportional hazard regression modeling. Results: The results demonstrated that increased AFPwas associated with longer prothrombin time (PTs), liver capsule invasion, low grade differentiation, and lateBarcelona Clinic Liver Center (BCLC) stage. Moreover, the female patients had a greater prevalence of increasedpreoperative AFP than male patients [284.8 (3.975-3167.5) vs (3.653-140.65); Z-2.895, p=0.004]. The 1-, 3-, and5-year recurrence-free survival (RFS) rates were 78.1, 57.5, and 40.6 % in the AFP-negative group and 61.8,37.7, and 31.4 %, respectively, in the AFP-positive group (log-rank test 8.312, p=0.004). The 1-, 3-, and 5-yearoverall survival (OS) rates were 94.4, 83.8, and 62.3% in the AFP-negative group and 87.2, 60.0, and 36.7%,respectively, in the AFP-positive group. The difference was statistically significant (log-rank test, 16.884, p=0.000).Cox proportional-hazards model identified preoperative AFP to be an independent prognostic predictor of overallsurvival. Conclusions: Preoperative serum AFP is an independent predictor of prognosis among HCC patientsfollowing surgical resection. Female patients have a higher preoperative AFP than their male counterparts.  相似文献   

13.
Background and aimThe impact of currently clinically significant portal hypertension (CSPH) for patients with early-stage HCC after surgery remains controversial. The purpose of this study is to understand the specific effect of CSPH on patients with early-stage (BCLC A stage) HCC after surgery.MethodsWe collected data from 386 HCC patients treated at two centers from December 2009 to January 2017.224 patients (all treated by hepatectomy) were in BCLC stage A, of which, 122 had no CSPH, and 102 had CSPH. There were 162 patients in BCLC stage B (who underwent surgery, TACE, and conservative treatment). The prognosis of the CSPH and non-CSPH groups in BCLC stage A was compared using the Kaplan-Meier method. We used multivariate Cox regression to analyze prognostic factors in patients in BCLC stage A and compared the prognosis of the two groups with the BCLC stage B group.ResultsAmong the 224 BCLC stage A patients after surgery, the overall survival (OS) and recurrence-free survival (RFS) of the CSPH group were worse than those of the non-CSPH group (P < 0.001, HR = 2.340[1.554–3.523]; P < 0.001, HR = 2.577[1.676–3.812]) The multivariate Cox proportional hazards model indicated that CSPH was an independent prognostic factor for OS and RFS in BCLC stage A patients. BCLC stage A patients with CSPH treated by hepatectomy had a comparable prognosis to BCLC B stage patients (P = 0.378), and the OS and RFS (P = 0.229; P = 0.077) in the CSPH (BCLC A) group were also comparable to BCLC stage B patients treated with surgery alone.ConclusionsCSPH can affect the surgical prognosis of early-stage (BCLC stage A) HCC. BCLC stage A patients with CSPH have a prognosis comparable to patients with BCLC stage B. An additional stage, such as the BCLC stage A-B, can be considered.  相似文献   

14.
BACKGROUND AND OBJECTIVES: The objective of this investigation was to study the clinicopathological factors influencing long-term outcome of hepatocellular carcinoma (HCC) with liver cirrhosis in patients undergoing hepatectomy. Liver cirrhosis, especially the macronodular variety, has been found in up to 90% of patients with HCC. In Asia, the incidence of liver cirrhosis in patients with HCC who had undergone hepatic resection varies from 42.5% to 73.8%. However, the optimal surgical approach for HCC patients with cirrhosis is less clearly defined. Resection of the cirrhotic liver is challenging and remains controversial in the treatment of HCC. METHODS: This study retrospectively analyzed the surgical outcomes of HCC concomitant with liver cirrhosis in 218 patients who underwent hepatic resection between 1986 and 1998. Post-resection prognostic factors were assessed using a univariate log-rank test and a multivariate Cox proportional hazards model. RESULTS: The overall postoperative complication rate was 15.6%, while the surgical mortality rate was 8.8%. Meanwhile, the 1-, 3-, and 5-year disease-free survival rates were 50.9%, 33.98%, and 27.03%, respectively, and. the overall cumulative survival rates at 1, 3, and 5 years were 63.14%, 41.88%, and 31.83%, respectively. Applying Cox's multivariate proportional hazard model indicated that significant adverse prognostic indicators included elevated alkaline phosphatase value, tumor size >2 cm, presence of satellite lesions, and vascular invasion. CONCLUSIONS: This investigation found that overall survival for HCC patients concomitant with liver cirrhosis who underwent hepatic resection should be stratified on the basis of the high value of alkaline phosphatase, tumor size, satellite lesions, and vascular invasion.  相似文献   

15.
Backgrounds: Recently Hong Kong Liver Cancer (HKLC) staging system has been proposed for staging of hepatocellular carcinoma (HCC), and has been shown to provide better prognostic ability than the Barcelona Clinic Liver Cancer (BCLC) system. However, the HKLC system lacks external validation, and its applicability remains uncertain. The present study was aimed to evaluate the prognostic performance of HKLC in HCC patients treated with curative intent. Methods: Medical records of HCC patients treated with either resection or radiofrequency ablation (RFA) from 2011 to 2016 were retrospectively reviewed. The overall survival and the prognostic ability of the HKLC and BCLC system were evaluated. Results: 79 HCC patients were included, of which 64.56% had Child A cirrhosis. Chronic viral hepatitis B infection was the leading cause of HCC, followed by chronic viral hepatitis C infection, alcohol and alcohol with HBV or HCV infection. According to the BCLC system, 82.28% were in stage 0-A, and according to the HKLC system, 93.67% were in stage I-IIb. RFA and liver resection were the primary treatment in 56.96% and 43.04%, respectively. The 5-year survival rate of patients in HKLC stage I, IIa and IIb were 81.64%, 61.66%, and 54.42%, respectively (P<0.001). Whereas, the 5-year survival rate of patients in BCLC stage 0, A and B were 60.00%, 75.90%, and 26.65%, respectively (P=0.053). The AUROC curve of the HKLC and BCLC for the entire cohort was 0.77 and 0.64, respectively (P=0.15). Subgroup analysis showed the AUROC curve of the HKLC and BCLC for the patients with viral-associated HCC was 0.79 and 0.68, respectively (P=0.02). Conclusions: Applying the HKLC staging system provides a good discriminative ability for survival prediction in HCC patients treated with curative intent. Comparing with the BCLC system, the HKLC system tends to yield better prognostic accuracy, particularly in viral-associated HCC.  相似文献   

16.
目的:探讨肝细胞癌(hepatocellular carcinoma,HCC)患者血清总胆汁酸水平升高的影响因素.方法:回顾性收集2015年1月至2017年1月于我院介入病房收治肝细胞癌的资料,同时选取健康患者作为对照组,采用Logistic回归模型分析肝癌患者血清总胆汁酸(serum total bile acid,TBA)水平升高的影响因素.结果:共147例患者纳入研究,肝癌患者TBA水平较健康者升高(t=-12.53,P<0.001);HCC组,肝细胞癌BCLC分期,两两比较显示A期与B期,P=0.53 >0.05,差异无统计学意义;余两两之间比较,P<0.001,差异均具有统计学意义.肝功能Child-Pugh分级A/B/C级,两两之间比较,A级与B级比较,P=0.075 >0.05,差异无统计学意义.余A级与C级、B级与C级相比较,均显示P <0.05,差异有统计学意义.Logistic回归分析结果显示,影响TBA水平升高的因素分别是病毒性肝炎、肝硬化、肝功能Child-Pugh分级、肝癌BCLC分期,其OR值依次为2.10、2.03、1.91、1.87,P<0.05.结论:病毒性肝炎、肝硬化、肝癌BCLC分期及肝功能Child-Pugh分级为肝细胞癌患者TBA水平升高的影响因素.  相似文献   

17.
残癌危险因素对肝癌切除术后肝动脉栓塞化疗效果的影响   总被引:6,自引:0,他引:6  
Ren ZG  Lin ZY  Xia JL  Zhang BH  Ye SL  Chen SY  Gan YH  Wu XF  Chen Y  Ge NL  Wu ZQ  Ma ZC  Zhou XD  Fan J  Qin LX  Ye QH  Sun HC  Zhou J  Tang ZY 《中华肿瘤杂志》2004,26(2):116-118
目的 探讨术后辅助性肝动脉栓塞化疗对残癌低危和残癌高危患者预后的不同影响。方法 进入研究的病例分为干预组(辅助性动脉栓塞化疗组)和对照组(未行辅助性动脉栓塞化疗),根据残癌的高危因素将肝癌切除术的患者分为残癌高危者和残癌低危者,采用病例对照实验设计,以单因素统计方法和Cox模型,分析研究术后辅助性肝动脉栓塞化疗对肝癌切除术患者预后的影响,以及残癌高危因素对辅助性动脉栓塞化疗作用的影响。结果 对于残癌低危患者,干预组和对照组术后1,2,3,4年生存率分别为97.2%、78.0%、66.5%、66.5%和91.2%、81.4%、70.3%、54.4%,生存率差异无显著性(P=0.7667);而对于残癌高危患者,干预组和对照组术后1,2,3,4年生存率分别为89.5%、73.4%、59.2%、53.8%和70.5%、61.9%、46.8%、46.8%,生存率差异有显著性(P=0.0029)。Cox比例风险模型分析结果显示,辅助性动脉栓塞化疗对切除术后肝癌患者预后的影响,决定于患者有无残癌的危险因素,辅助性动脉栓塞化疗不是影响患者预后的独立因素。结论 术后给予辅助性肝动脉栓塞化疗,可延长有残癌高危因素患者的生存期,而对于无残癌危险因素的患者,术后辅助性肝动脉栓塞化疗不能延长生存期。  相似文献   

18.
Background: The hepatocellular carcinoma is very common in China. Our aim in this report was to investigate clinical and pathological factors based on the current decade data that could influence prognosis of HCC patients after hepatectomy. Methods: Between 2002 and 2009, all patients undergoing hepatectomy for HCC were followed up and reviewed retrospectively. Prognostic factors were studied by univariate and multivariate analysis, with Kaplan-Meier and Cox multivariate survival analyses. Results: Complete clinicopathologic and follow-up data were available for 114 patients. The estimated cumulative survival rates at 1, 3, and 5 yr were 84.6%, 60.2% and 51.8%, respectively. On univariate analysis, key prognostic factors were AFP level, GGT level, tumor size, number of tumors, portal vein invasion, liver cirrhosis status and TNM stage. In the multivariate analysis, tumor size, GGT level, liver cirrhosis status and portal vein invasion were significantly associated with patients’ prognosis. Conclusion: Through follow-up of a relatively large cohort of Chinese patients, tumor size, GGT level, liver cirrhosis status, portal vein invasion were revealed as important factors for long-term survival after hepatectomy. Early diagnosis for tumor and the improvement of liver function before surgery are important ways to improve the prognosis.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号